These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 14158954)

  • 41. Enzyme studies on human blood. VIII. The effect of fibrinogen concentration on the thrombin clotting time.
    SHINOWARA GY; ROSENFELD L
    J Lab Clin Med; 1951 Feb; 37(2):303-10. PubMed ID: 14814357
    [No Abstract]   [Full Text] [Related]  

  • 42. Coincident classic hemophilia and "idiopathic" thrombocytopenic purpura in patients under treatment with concentrates of antihemophilic factor (factor VIII).
    Ratnoff OD; Menitove JE; Aster RH; Lederman MM
    N Engl J Med; 1983 Feb; 308(8):439-42. PubMed ID: 6401839
    [No Abstract]   [Full Text] [Related]  

  • 43. [Spontaneous splenic rupture in a child with hemophilia].
    Gruminskiĭ VS; Grechanyĭ VP
    Vestn Khir Im I I Grek; 1990 Apr; 144(4):69-70. PubMed ID: 2173236
    [No Abstract]   [Full Text] [Related]  

  • 44. Immunologic dysfunction in patients with classic hemophilia receiving lyophilized factor VIII concentrates and cryoprecipitate.
    Tsoukas C; Gervais F; Fuks A; Guttmann RD; Strawczynski H; Shuster J; Gold P
    Can Med Assoc J; 1983 Oct; 129(7):713-7. PubMed ID: 6225504
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Transfusion of human plasma poor in fibrinogen in hemophilia A].
    van CREVELD ; MOCHTAR IA
    Hemostase; 1961; 1():75-7. PubMed ID: 13882172
    [No Abstract]   [Full Text] [Related]  

  • 46. Long-acting factor VIII for hemophilia A creates hope for less taxing treatment.
    Morrow T
    Manag Care; 2014 Jul; 23(7):46-7. PubMed ID: 25199371
    [No Abstract]   [Full Text] [Related]  

  • 47. Physiologic considerations in the management of hemophilia.
    Briggs DK
    Pathobiol Annu; 1971; 1():205-14. PubMed ID: 4950380
    [No Abstract]   [Full Text] [Related]  

  • 48. Heparin small pool high yield purified factor VIII: in vivo recovery and half-life of routinely produced freeze-dried concentrate.
    Smit Sibinga CT; Daenen SM; van Imhoff GW; Maas A; Das PC
    Thromb Haemost; 1984 Feb; 51(1):12-5. PubMed ID: 6426077
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX].
    Iizuka A; Kuwashima M; Nagao T
    Nihon Ketsueki Gakkai Zasshi; 1982 Sep; 45(5):987-92. PubMed ID: 6818811
    [No Abstract]   [Full Text] [Related]  

  • 50. Bladder neck obstruction in a 6-month-old hemophiliac infant: successful surgical repair with the aid of fibrinogen rich in factor VIII.
    IRWIN AR; LILES WB; BLANCHARD RJ
    J La State Med Soc; 1962 Oct; 114():362-5. PubMed ID: 13956727
    [No Abstract]   [Full Text] [Related]  

  • 51. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vivo bypass of hemophilia A coagulation defect by factor XIIa implant.
    Ton-That TT; Doron D; Pollard BS; Bacher J; Pollard HB
    Nat Biotechnol; 2000 Mar; 18(3):289-95. PubMed ID: 10700143
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Treatment of hemophilia with immunologic inhibitor of factor VIII by using "activated" coagulant fractions].
    Sultan Y; Brouet JC
    Nouv Presse Med; 1975 Oct; 4(36):2571-4. PubMed ID: 1081682
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [ON CHEMICAL COMPOSITION OF FIBRINOGEN AND FIBRIN. V. GLYCIDIC COMPONENTS OF PLASMATIC FIBRIN IN HEMOPHILIA].
    CHIARIONI T; NARDI E; BENI G
    Prog Med (Napoli); 1964 Oct; 20():666-9. PubMed ID: 14272803
    [No Abstract]   [Full Text] [Related]  

  • 55. The efficacy and safety of lyophilized cryoprecipitate in hemophilia A.
    Chuansumrit A; Isarangkura P; Chantanakajornfung A; Kuhathong K; Pintadit P; Jitpraphai C; Hathirat P; Nuchprayoon C
    J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S69-73. PubMed ID: 10730521
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lyophilised plasmas for one-stage determination of factor VIII.
    Sikorová J; Vorlová Z
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1980; 107(6):906-13. PubMed ID: 6162757
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New treatment for hemophilia.
    FDA Consum; 2003; 37(6):5. PubMed ID: 14983810
    [No Abstract]   [Full Text] [Related]  

  • 58. Surgical complications in a hemophilia patient with factor VIII inhibitor and their endovascular management.
    Sadat U; Naik J; Hayes PD
    Vasc Endovascular Surg; 2008; 42(2):168-72. PubMed ID: 18421033
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Freeze-dried whole plasma: evaluating sucrose, trehalose, sorbitol, mannitol and glycine as stabilizers.
    Bakaltcheva I; O'Sullivan AM; Hmel P; Ogbu H
    Thromb Res; 2007; 120(1):105-16. PubMed ID: 16962645
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [TECHNIC OF TRANSFUSION THERAPY IN SURGERY ON HEMOPHILIACS].
    ABDULLAEV GM; KOZHEVNIKOV IN
    Probl Gematol Pereliv Krovi; 1964 Aug; 9():36-40. PubMed ID: 14252414
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.